MOLECULAR PATHOLOGY SHARED RESOURCE (Core-957) ABSTRACT Overview: The Molecular Pathology Shared Resource (MPSR) consists of 3 thematically related and operationally coordinated business units (Histology, Cytogenetics and Pre-analytical Evaluation and Molecular Testing (PEMT)). MPSR supports translational and clinical research projects of UCCC members by providing clinical-grade services and molecular assays for analysis of pre-clinical and patient samples at reduced prices, greatly facilitating cancer research. Equipment: Major equipment: Histology unit has tissue processors and embedding stations, microtomes and automated staining equipment; Cytogenetics unit has high-quality Zeiss fluorescence microscopes equipped with last generation cameras and automated interference filter wheels; PEMT has Next Generation Sequencers (NGS), capillary electrophoresis, real-time PCR among others. Services: MPSR offers pathologist examination of tissue samples, tumor sample microdissection, standard and customizable histologic tissue processing and staining, cytogenetic techniques (ploidy analyses, G-banding and spectral karyotyping, metaphase FISH with single locus and painting probes, interphase FISH using 2-target to 6-target multiplexing), and a wide range of nucleic acid-based assays (Sanger sequencing, next-generation sequencing, quantitative PCR, micro-satellite instability testing). Activities in the Histology and PEMT units are performed in a CLIA-certified, CAP-inspected environment by dedicated technologists, resulting in clinical-grade data while those in Cytogenetics are GLP. All data is provided in an analyzed format and include bioinformatic analysis of complex data sets, coupled with comprehensive interpretation of results and illustrative documentation. The MPSR also supports and aids in the design, implementation, and validation of custom assays both for specific investigator use and for wider use by the UCCC community. Consultation and Education: The MPSR offers consultation, as well as one-on-one and group educational sessions for all services and assays, for both assay design and data analysis. Instructional sessions are offered to UCCC members, in order for users to precisely understand which assays may best serve their individual translational research needs. Management: The MPSR is a UCCC shared resource managed by the Cancer Center. CCSG funding represents 21% of the annual operating budget. The remaining support comes from user fees (79%). MPSR is overseen by UCCC Associate Director for Translational Research. Use of Services: Since July 2011, 147 investigators have used the services. 78% percent of users were UCCC members, representing all 6 Programs and resulting in 118 publications. Future Directions: The MPSR has a number of future directions that will enhance the SR and UCCC member cancer research: 1) The PEMT unit will significantly expand NGS capabilities, increasing the number of genes analyzed in panels and the types of alterations that can be detected; 2) The Cytogenetics unit will introduce RNA FISH capabilities and automated scanning and computer-assisted analyses for FISH in cell suspensions and tissue sections.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA046934-29
Application #
9207580
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Project Start
Project End
Budget Start
2017-02-01
Budget End
2018-01-31
Support Year
29
Fiscal Year
2017
Total Cost
$289,535
Indirect Cost
$103,339
Name
University of Colorado Denver
Department
Type
Domestic Higher Education
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Harder, Bryan; Tian, Wang; La Clair, James J et al. (2017) Brusatol overcomes chemoresistance through inhibition of protein translation. Mol Carcinog 56:1493-1500
Chen, Yufei; Anastassiadis, Konstantinos; Kranz, Andrea et al. (2017) MLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged Acute Myeloid Leukemia. Cancer Cell 31:755-770.e6
DeRyckere, Deborah; Lee-Sherick, Alisa B; Huey, Madeline G et al. (2017) UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models. Clin Cancer Res 23:1481-1492
Scarborough, Hannah A; Helfrich, Barbara A; Casás-Selves, Matias et al. (2017) AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition. Clin Cancer Res 23:1531-1541
Neelakantan, Deepika; Zhou, Hengbo; Oliphant, Michael U J et al. (2017) EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nat Commun 8:15773
Barón, Anna E; Kako, Severine; Feser, William J et al. (2017) Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer. J Thorac Oncol 12:1512-1523
Todd, Maria C; Langan, Thomas A; Sclafani, Robert A (2017) Doxycycline-Regulated p16MTS1 Expression Suppresses the Anchorage-Independence and Tumorigenicity of Breast Cancer Cell Lines that Lack Endogenous p16. J Cancer 8:190-198
Brown, Dustin G; Borresen, Erica C; Brown, Regina J et al. (2017) Heat-stabilised rice bran consumption by colorectal cancer survivors modulates stool metabolite profiles and metabolic networks: a randomised controlled trial. Br J Nutr 117:1244-1256
Haverkos, Bradley M; Abbott, Diana; Hamadani, Mehdi et al. (2017) PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood 130:221-228
Shearn, Colin T; Saba, Laura M; Roede, James R et al. (2017) Differential carbonylation of proteins in end-stage human fatty and nonfatty NASH. Free Radic Biol Med 113:280-290

Showing the most recent 10 out of 1448 publications